A20GS-9822, a preclinical LEDGIN, displays a block-and-lock phenotype in cell cultureOn-demand oral abstract sessionEliminating and silencing latency
A5Proteomic evidence of vesatolimod-induced enhancement of 'cross-talk' between innate and adaptive immune cells in HIV controllers on ARTOn-demand oral abstract sessionInnate immunity
A9The circadian clock machinery regulates HIV transcription in CD4+ T cellsOn-demand oral abstract sessionSystemic immune activation and inflammation
A23RNA-directed gene therapy protects CD4+ T cells during HIV challenge and delays virus rebound post-ART in humanized miceOn-demand oral abstract sessionGene therapy
A21The balance of mucosal CD4 T cells prior to infection is associated with control of virus replication after therapeutic vaccination in SIV-infected rhesus macaquesOn-demand oral abstract sessionImmunotherapy: Vaccines and antibodies
A25Early antiretroviral therapy favors post-treatment SIV control, which is associated with enhanced CD8+ T-cell antiviral activity against rebounding virus ' the pVISCONTI studyOn-demand oral abstract sessionHIV-1 controllers (including post-treatment controllers) and long-term non-progressors
A19Evaluation of HIV-1 reservoir size and broadly neutralizing antibody (bNAb) susceptibility in individuals who initiated ART during acute and chronic infectionOn-demand oral abstract sessionCharacterizing HIV/SIV reservoirs and rebounding virus
B80Robust SARS-CoV-2-specific serological and functional t-cell immunity in PLWHIVOn-demand oral abstract sessionImmune responses against SARS-CoV2 in PLWHIV
B30Rising substance use linked to STI and HCV in Thai MSM after acute HIV infectionOn-demand oral abstract sessionSubstance abuse (including opioid use disorder)
B13High HCV cure rates in C-FREE, first community-based study offering testing and treatment of viral hepatitis and HIV among people who use drugs and their partners in ThailandOn-demand oral abstract sessionViral hepatitis C
11 - 20 of 870 items